ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.31B
Close$
Share Statistics
| Market cap | $1.31 Billion |
|---|---|
| Enterprise Value | $1.03 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.51 |
| Beta | 0.2 |
| Outstanding Shares | 431,391,000 |
Return
| Return on Equity | -84.97% |
|---|---|
| Return on Assets | -51.62% |
| Return on Invested Capital | -80.31% |
Valuation & Multiples
| P/E Ratio | -5.02 |
|---|---|
| PEG | -66.01 |
| Price to Sales | - |
| Price to Book Ratio | 3.13 |
| Enterprise Value to Revenue | 3.75 |
| Enterprise Value to EBIT | -1.95 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | 0.58 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
202 employees
CEO: Wenzhi Tian ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule cur...